Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
13.61
+0.11 (0.81%)
At close: Apr 28, 2026, 4:00 PM EDT
13.62
+0.01 (0.07%)
After-hours: Apr 28, 2026, 7:39 PM EDT
Viridian Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Viridian Therapeutics stock have an average target of 35.46, with a low estimate of 20 and a high estimate of 61. The average target predicts an increase of 160.54% from the current stock price of 13.61.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Viridian Therapeutics stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 6 | 6 | 6 | 6 |
| Buy | 4 | 6 | 6 | 6 | 6 | 7 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 13 | 13 | 13 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $36 → $33 | Strong Buy | Maintains | $36 → $33 | +142.47% | Apr 21, 2026 |
| Wedbush | Wedbush | Buy Maintains $37 → $31 | Buy | Maintains | $37 → $31 | +127.77% | Apr 8, 2026 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $36 → $31 | Strong Buy | Maintains | $36 → $31 | +127.77% | Apr 7, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $42 → $30 | Buy | Maintains | $42 → $30 | +120.43% | Apr 7, 2026 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $45 → $32 | Buy | Maintains | $45 → $32 | +135.12% | Apr 2, 2026 |
Financial Forecast
Revenue This Year
80.58M
from 70.85M
Increased by 13.73%
Revenue Next Year
305.40M
from 80.58M
Increased by 279.00%
EPS This Year
-4.09
from -3.32
EPS Next Year
-2.34
from -4.09
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 217.7M | 665.2M | ||||||
| Avg | 80.6M | 305.4M | ||||||
| Low | 18.6M | 131.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 207.2% | 725.5% | ||||||
| Avg | 13.7% | 279.0% | ||||||
| Low | -73.7% | 63.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.87 | -0.76 | ||||||
| Avg | -4.09 | -2.34 | ||||||
| Low | -5.90 | -4.83 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.